Learn languages naturally with fresh, real content!

Popular Topics
Explore By Region
A UK study tests AI to improve prostate cancer treatment decisions using biopsy data and long-term patient outcomes.
A new University of Oxford-led study, funded by Prostate Cancer UK, is testing whether AI can improve prostate cancer treatment decisions by analyzing biopsy samples with at least five years of patient follow-up data.
The Vanguard Path study, involving three NHS sites, aims to help doctors better assess cancer aggressiveness, potentially reducing unnecessary surgeries or radiotherapy.
The AI tool, developed by Artera, will be evaluated in real clinical settings, particularly where treatment decisions are uncertain.
This effort follows another NHS trial using AI to prioritize high-risk MRI scans for faster diagnosis.
Prostate cancer, the most common cancer in men, had over 58,000 diagnoses in England in 2024.
Researchers say the study could provide key evidence for wider NHS adoption of AI in prostate cancer care.
Un estudio del Reino Unido prueba la IA para mejorar las decisiones de tratamiento del cáncer de próstata utilizando datos de la biopsia y los resultados a largo plazo de los pacientes.